High OX40 expression in recurrent ovarian carcinoma is indicative for response to repeated chemotherapy

BMC Cancer

Table 5 Patients’ characteristics according to dichotomized distribution of OX40 expression by tumor cells in primary cancer biopsies in the overall cohort (cut-off = 144.5; n = 47)^a

	OX40 high	OX40 low	p-value
	n = 27 (100%)	n = 20 (100%)
Age (median, range)	58 (34–73)	64 (39–77)	0.197
FIGO stage
II	1 (3.7)	0	0.643
IIIA	0	1 (5.0)
IIIB	4 (14.8)	1 (5.0)
IIIC	18 (66.7)	14 (70.0)
IV	4 (14.8)	4 (20.0)
Residual disease
None	11 (40.7)	5 (25.0)	0.277
< 2 cm	10 (37.0)	7 (35.0)
> 2 cm	5 (18.5)	8 (40.0)
Numbers of chemotherapy cycles
< 6	3 (11.1)	4 (20.0)	0.428
6 or more	23 (85.2)	16 (80.0)	0.428
CS^b	20 (74.1)	13 (65.0)	0.501
CR^b	7 (25.9)	7 (35.0)	0.501
6-month RFS % (95%CI)^c	0.56 (0.35–0.72)	0.50 (0.27–0.69)	0.472
3-year OS % (95%CI)^c	0.43 (0.22–0.62)	0.45 (0.17–0.71)	0.869

^apercentages may not add to 100% due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random. Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kaplan-Meier method. FIGO stage, residual disease, numbers of chemotherapy cycles and chemoresistance were analyzed using the Chi-Square or the Fisher’s Exact test
^bCS chemosensitive, CR chemoresistant
^cRFS recurrence-free survival, OS overall survival

ISSN: 1471-2407